Overall, the results from preclinical in vivo studies of fecal transfer in a murine model of melanoma [213] and sequencing of the gut microbiota composition from 42 melanoma patients treated with anti-PD-1 [214] suggest a correlation between the presence of Bifidobacterium species and clinical response to this immunotherapy. This evidence concerns the gene PDCD1 and melanoma.